Physician profile
Farhad Karim
NPI 1184701336
$1,870.94
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $182 · 2021: $150.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $346.32 | 2019-2020 | |
| Alk-Abello, INC | $323.11 | 2019-2021 | |
| Glaxosmithkline, LLC. | $301.03 | 2019 | |
| Genzyme Corporation | $265.25 | 2019-2020 | |
| Csl Behring | $232.26 | 2019-2020 | |
| Genentech USA, INC. | $146.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $122.55 | 2019-2020 | |
| Shire North American Group INC | $52.24 | 2019 | |
| Pfizer INC. | $28.18 | 2019-2020 | |
| Optinose US, INC. | $20.47 | 2019 | |
| Pharming Healthcare, INC. | $20.27 | 2019 | |
| Covis Pharma Gmbh | $12.76 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.